Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Rheumatology | Musculoskeletal | Immunology | Family Medicine
Disease Category: Rheumatoid Arthritis
Location: United States, GA
A Phase 2, 12-week, double-blind, randomized, parallel group, placebo-controlled study of four doses of Study Medication in subjects with moderate to severe rheumatoid arthritis
This study is designed to evaluate safety and assess initial efficacy of Study Medication, a JAK3 inhibitor, for treatment of subjects with active RA. This study will assess the clinical response of 4 doses of Study Medication compared to placebo when administered for 12 weeks to patients with active RA. The study will also evaluate the safety and tolerability of Study Medication compared to placebo when administered for 12 weeks to subjects with active RA.
Patient Inclusion Criteria:
Patient Exclusion Criteria:
CW ID: 165443
Date Last Changed:
July 23, 2013
Suzi DeFiesta, Research AdministratorCSI Research Inc11379 Southbridge Parkway, Suite BAlpharetta, GA 30022Phone: 770-667-0220Fax: 770-667-0227
CSI Research Inc
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2017 CenterWatch.